Focused On-demand Library for Rho-related GTP-binding protein RhoF

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HBH0

UPID:

RHOF_HUMAN

Alternative names:

Rho family GTPase Rif; Rho in filopodia

Alternative UPACC:

Q9HBH0; Q8WVB1; Q9NXH6

Background:

Rho-related GTP-binding protein RhoF, also known as Rho family GTPase Rif and Rho in filopodia, is a plasma membrane-associated small GTPase. It plays a crucial role in cellular processes by cycling between an active GTP-bound and an inactive GDP-bound state. This protein is instrumental in the formation of filopodia, thin, actin-rich surface projections, and works in conjunction with CDC42 and Rac to diversify actin-based morphology.

Therapeutic significance:

Understanding the role of Rho-related GTP-binding protein RhoF could open doors to potential therapeutic strategies. Its pivotal function in actin dynamics and cell morphology underscores its potential as a target in diseases where these processes are dysregulated.